Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
